The Washington Cancer Institute is Washington, D.C.'s largest cancer care provider, treating more cancer patients than any other program in the nation's capital. The Washington Cancer Institute opened on May 9, 1992.

During the past decade, Washington Cancer Institute conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 37 clinical trials were completed, i.e. on average, 264.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 14 clinical trials were completed. i.e. 350% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Washington Cancer Institute" #1 sponsor was "Medstar Health Research Institute" with 9 trials, followed by "NSABP Foundation Inc" with 8 trials sponsored, "Alliance for Clinical Trials in Oncology" with 6 trials sponsored, "Hoffmann-La Roche" with 6 trials sponsored and "Radiation Therapy Oncology Group" with 6 trials sponsored. Other sponsors include 51 different institutions and companies that sponsored additional 48 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Washington Cancer Institute" #1 collaborator was "National Cancer Institute (NCI)" with 27 trials as a collaborator, "Genentech, Inc." with 6 trials as a collaborator, "Bristol-Myers Squibb" with 4 trials as a collaborator, "NRG Oncology" with 3 trials as a collaborator and "SWOG Cancer Research Network" with 3 trials as a collaborator. Other collaborators include 34 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "Washington Cancer Institute" are "Breast Cancer" (22 trials), "Colorectal Cancer" (6 trials), "Lung Cancer" (4 trials), "Prostate Cancer" (4 trials) and "Gastrointestinal Stromal Tumors" (3 trials). Many other conditions were trialed in "Washington Cancer Institute" in a lesser frequency.

Most popular intervention types in "Washington Cancer Institute" are "Drug" (78 trials), "Radiation" (11 trials), "Other" (10 trials), "Biological" (9 trials) and "Procedure" (9 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Trastuzumab" (8 trials), "Docetaxel" (5 trials), "Paclitaxel" (5 trials) and "Carboplatin" (4 trials). Other intervention names were less common.

The vast majority of trials in "Washington Cancer Institute" are 65 trials for "All" genders, 18 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Washington Cancer Institute". undefined are not yet recruiting, undefined are recruiting, 20 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 48 completed trials in Washington Cancer Institute, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Washington Cancer Institute, 2 "Phase 1" clinical trials were conducted, 35 "Phase 2" clinical trials and 45 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".